Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
19
07
2022
accepted:
30
10
2022
pubmed:
9
12
2022
medline:
3
2
2023
entrez:
8
12
2022
Statut:
ppublish
Résumé
Nitrofurantoin has been re-introduced as a first-choice antibiotic to treat uncomplicated acute urinary tract infections in England and Wales. Highly effective against common uropathogens such as Escherichia coli, its use is accompanied by a low incidence (<10%) of antimicrobial resistance. Resistance to nitrofurantoin is predominantly via the acquisition of loss-of-function, step-wise mutations in the nitroreductase genes nfsA and nfsB. To explore the in situ evolution of NitR in E. coli isolates from 17 patients participating in AnTIC, a 12-month open label randomized controlled trial assessing the efficacy of antibiotic prophylaxis in reducing urinary tract infections (UTIs) incidence in clean intermittent self-catheterizing patients. The investigation of NitR evolution in E. coli used general microbiology techniques and genetics to model known NitR mutations in NitSE. coli strains. Growth rate analysis identified a 2%-10% slower doubling time for nitrofurantoin resistant strains: NitS: 20.8 ± 0.7 min compared to NitR: 23 ± 0.8 min. Statistically, these data indicated no fitness advantage of evolved strains compared to the sensitive predecessor (P-value = 0.13). Genetic manipulation of E. coli to mimic NitR evolution, supported no fitness advantage (P-value = 0.22). In contrast, data argued that a first-step mutant gained a selective advantage, at sub-MIC (4-8 mg/L) nitrofurantoin concentrations. Correlation of these findings to nitrofurantoin pharmacokinetic data suggests that the low incidence of E. coli NitR, within the community, is driven by urine-based nitrofurantoin concentrations that selectively inhibit the growth of E. coli strains carrying the key first-step loss-of-function mutation.
Sections du résumé
BACKGROUND
Nitrofurantoin has been re-introduced as a first-choice antibiotic to treat uncomplicated acute urinary tract infections in England and Wales. Highly effective against common uropathogens such as Escherichia coli, its use is accompanied by a low incidence (<10%) of antimicrobial resistance. Resistance to nitrofurantoin is predominantly via the acquisition of loss-of-function, step-wise mutations in the nitroreductase genes nfsA and nfsB.
OBJECTIVE
To explore the in situ evolution of NitR in E. coli isolates from 17 patients participating in AnTIC, a 12-month open label randomized controlled trial assessing the efficacy of antibiotic prophylaxis in reducing urinary tract infections (UTIs) incidence in clean intermittent self-catheterizing patients.
METHODS
The investigation of NitR evolution in E. coli used general microbiology techniques and genetics to model known NitR mutations in NitSE. coli strains.
RESULTS
Growth rate analysis identified a 2%-10% slower doubling time for nitrofurantoin resistant strains: NitS: 20.8 ± 0.7 min compared to NitR: 23 ± 0.8 min. Statistically, these data indicated no fitness advantage of evolved strains compared to the sensitive predecessor (P-value = 0.13). Genetic manipulation of E. coli to mimic NitR evolution, supported no fitness advantage (P-value = 0.22). In contrast, data argued that a first-step mutant gained a selective advantage, at sub-MIC (4-8 mg/L) nitrofurantoin concentrations.
CONCLUSION
Correlation of these findings to nitrofurantoin pharmacokinetic data suggests that the low incidence of E. coli NitR, within the community, is driven by urine-based nitrofurantoin concentrations that selectively inhibit the growth of E. coli strains carrying the key first-step loss-of-function mutation.
Identifiants
pubmed: 36480295
pii: 6883940
doi: 10.1093/jac/dkac398
pmc: PMC9890214
doi:
Substances chimiques
Nitrofurantoin
927AH8112L
Anti-Bacterial Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
373-379Subventions
Organisme : NIHR HTA
ID : 11/72/01
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Clin Microbiol Infect. 2017 Jun;23(6):355-362
pubmed: 27542332
Drug Resist Updat. 2012 Jun;15(3):162-72
pubmed: 22516308
Eur Urol Open Sci. 2022 Feb 02;37:90-98
pubmed: 35243393
Curr Opin Microbiol. 2012 Oct;15(5):555-60
pubmed: 22878455
J Antimicrob Chemother. 2019 Jun 1;74(6):1656-1661
pubmed: 30859184
Pathogens. 2022 Mar 15;11(3):
pubmed: 35335681
Mol Syst Biol. 2006;2:2006.0007
pubmed: 16738553
J Antimicrob Chemother. 1994 May;33 Suppl A:23-30
pubmed: 7928834
J Antimicrob Chemother. 2008 Sep;62(3):495-503
pubmed: 18544599
Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S
pubmed: 12113866
Appl Environ Microbiol. 2015 Apr;81(7):2506-14
pubmed: 25636838
Int J Antimicrob Agents. 2018 Aug;52(2):226-232
pubmed: 29753133
PLoS One. 2020 May 14;15(5):e0232903
pubmed: 32407346
Microb Genom. 2021 Dec;7(12):
pubmed: 34860151
J Antimicrob Chemother. 2015 Sep;70(9):2456-64
pubmed: 26066581
Lancet Infect Dis. 2018 Sep;18(9):957-968
pubmed: 30037647
J Bacteriol. 1978 Jan;133(1):10-6
pubmed: 338576
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16
pubmed: 11420333
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
pubmed: 10829079
J Bacteriol. 2003 Jun;185(12):3567-74
pubmed: 12775694
Dtsch Arztebl Int. 2008 Sep;105(39):657-62
pubmed: 19626213
Mol Biol Evol. 2014 Jan;31(1):232-8
pubmed: 24170494
Proteins. 2013 Oct;81(10):1847-54
pubmed: 23609986
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29784837
Nat Rev Microbiol. 2014 Jul;12(7):465-78
pubmed: 24861036
Elife. 2019 Oct 21;8:
pubmed: 31633483
Sci Rep. 2017 Jan 24;7:41189
pubmed: 28117390
J Bacteriol. 1998 Nov;180(21):5529-39
pubmed: 9791100